Optimized Production Process

Process designed to maintain coagulation factors and inhibitors1,2*

Pre-virus Inactivation AreaOptimized integration of pooling 630 to 1,520 single units of fresh frozen plasma (FFP)
Fast thawing of the high-quality FFP
Cell and cell debris removal by filtration [1.0 μm]
S/D treatment (1% Tri[n- butyl] phosphate [TNBP]/1% Octoxynol-9)
Post-virus Inactivation AreaLiquid-phase extraction of TNBP
Clear filtration (0.45 μm)
Solid-phase extraction of Octoxynol-9
Affinity ligand chromatography for specific prion capture 
Sterile filtration (0.2 μm)
Aseptic AreaAseptic filling
Labeling and vacuum sealing
Freezing (≤-60oC) and storage (≤-30oC)
Full quality control and release

*Thrombosis can occur due to low levels of protein S. Excessive bleeding due to hyperfibrinolysis can occur
due to low levels of alpha2-antiplasmin also known as plasmin inhibitor.
The effectiveness of this step in removal of prion infectivity from the product has not been established.2

Octapharma’s manufacturing process sets the standard for safety in plasma collection and production

icon-clip-board Created with Sketch.

Learn how Octaplas’s manufacturing process helps minimize Transfusion Related Adverse Events (TRAEs).

Learn More
References:
  1. Octapharma. Data on file; 2013.
  2. Octaplas, Pooled Plasma (Human), Solvent/Detergent Treated Solution for Intravenous Infusion, complete prescribing information. 2019.